E-钙黏蛋白表达与乳腺癌临床病理学指标相关性的Meta分析

doi:10.3969/j.issn.1004-616x.2016.04.008

Abstract

Abstract: OBJECTIVE: To conduct a Meta-analysis for better understanding the relationship between E-cadherin and clinicopathological indicators in patients with breast cancer. METHODS: All eligible studies reporting associations between E-cadherin expression and clinicopathological features in breast cancer patients were retrieved from CBM, CNKI, PubMed and Cochrane Library databases. Review Manager 5.0 was used to calculate the pooled odds ratio (OR) and 95% confidence interval (CI). RESULTS: A total of 32 studies were included in this Meta-analysis. It was found that the expression level of E-cadherin was significantly correlated with lymph node metastasis[OR=0.27, 95%CI (0.18, 0.41), P<0.05], histological grades[OR=0.50, 95%CI(0.33, 0.77), P<0.05], clinical stage[OR=0.43, 95%CI(0.24, 0.76), P<0.05]. CONCLUSION: Aberrant expression of E-cadherin may play an important role in the progression and metastasis of breast cancer. In addition, aberrent E-cadherin may be a biomarker for early diagnosis and for development of individual therapy.

Key words: E-cadherin, breast cancer, Meta analysis, lymphatic metastasis

CLC Number:

R73-31

MO Qianzhen, SHEN Jiaxin, CHEN Minna, LIU Jing. Meta-analysis of the relationship between E-cadherin and clinicopathological indicators in patients with breast cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(4): 284-291.

References

[1] Burns WC,Thomas MC.The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology[J].Expert Rev Mol Med,2010,12:e17.
[2] 曾宪涛,刘慧,陈曦,等.Meta分析系列之四:观察性研究的质量评价工具[J].中国循证心血管医学杂志,2012,4(4):297-299.
[3] Zhou D,Zhang M,Xu P,et al.Expression of pigment epithelium-derived factor is associated with a good prognosis and is correlated with epithelial-mesenchymal transition-related genes in infiltrating ductal breast carcinoma[J].Oncol Lett,2016,11(1):116-124.
[4] 李刚,王青云,曾仲刚,等.乳腺癌及乳腺良性肿块的MRI征象与E-cadherin蛋白表达相关性研究[J].临床放射学杂志,2015,2015,34(6):898-902.
[5] 刘开泰,陆妙珍,江海峰.E-钙黏蛋白在浸润性乳腺癌分子分型中的差异性表达及临床病理意义[J].中国妇幼保健,2015,30(16):2632-2636.
[6] Cao YW,Wan GX,Sun JP,et al.Implications of the Notch1-Snail/Slug-epithelial to mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma[J].Kaohsiung J Med Sci,2015,31(2):70-76.
[7] 张一兵,卢鹤翔,张欣然,等.浸润性乳腺癌组织中E-cad基因表达和启动子甲基化的检测及其意义[J].吉林大学学报(医学版),2014,40(2):358-362.
[8] 白璐,高志安.乳腺癌中4.1N蛋白和E-cadherin蛋白表达的临床意义[J].医学与哲学(B),2014,35(4B):73-85.
[9] Guo S,Xu J,Xue R,et al.Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis[J].Int J Clin Oncol,2014,19(2):319-324.
[10] 张自森,薛长年,曹予文,等.E型钙黏附蛋白和多药耐药蛋白在乳腺浸润性导管癌中的表达及意义[J].实用医学杂志,2013,29(3):358-360.
[11] 洪荫,涂健,朱旬,等.乳腺癌组织中E-cad表达与EGFR、HER-2表达的关系[J].临床与实验病理学杂志,2013,29(11):1239-1241.
[12] Liu T,Zhang X,Shang M,et al.Dysregulated expression of Slug vimentin and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer[J].J Surg Oncol,2013,107(2):188-194.
[13] Pang H,Lu H,Song H,et al.Prognostic values of osteopontin-c E-cadherin and beta-catenin in breast cancer[J].Cancer Epidemiol,2013,37(6):985-992.
[14] Wang J,Zhao H,Tang D,et al.Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis[J].Cancer Biother Radiopharm,2013,28(4):283-288.
[15] 龙方懿,印国兵,刘智敏,等.HIF-1α、MT、Slug和E-cadherin在人乳腺癌中的表达及其意义[J].中国免疫学杂志,2012,28(6):502-506.
[16] 谭敏华,雷伟华,谭冬玲,等.浸润性乳腺癌ER、PR、HER-2、E-cadherin、CK5/6检测与临床预后关系[J].临床与实验病理学杂志,2011,27(9):933-938.
[17] 包俊杰,吴诚义.E-cadherin及N-cadherin在乳腺癌中表达的相关性及临床意义[J].中国普通外科杂志,2010,19(11):1253-1256.
[18] 段秀方,钟容,简莉人,等.CD44v6、E-Cadherin在乳腺癌中的表达及意义[J].中国妇幼保健,2010,25:3332-3334.
[19] 牛利刚,何建军,王珂,等.Her2阳性乳腺癌中β-catenin和E-cadherin异常表达及其意义[J].南方医科大学学报,2009,29(11):2237-2243.
[20] 刘琳,刘丽静,赵坡.乳腺癌组织中基质金属蛋白酶-2、基质金属蛋白酶-9和E-cadherin的表达及临床病理意义[J].中国现代医学杂志,2008,18(21):3149-3151.
[21] Zhang YG,Du J,Tian XX,et al.Expression of E-cadherin beta-catenin cathepsin D gelatinases and their inhibitors in invasive ductal breast carcinomas[J].Chin Med J,2007,120(18):1597-1605.
[22] 罗秉庆,郑绍光,唐青梅,等.COX-2、E-cadherin和KAI1在乳腺浸润性导管癌中的表达及意义[J].诊断病理学杂志,2007,14(3):215-217.
[23] 王秋鹏,顾华敏,王四玲.乳腺浸润性导管癌中E钙黏蛋白的表达与微血管密度的关系及意义[J].实用医学杂志,2007,23(9):1306-1308.
[24] 敖金娥.上皮钙黏附素在乳腺癌中的表达及其与临床生物学特性的关系[J].武汉大学学报(医学版),2007,28(3):362-364.
[25] 马春梅,蒋敏,李敏,等.浸润性乳腺癌组织中E-cadherin和CD44v6表达及DNA倍体分析[J].第四军医大学学报,2007,28(10):907-909.
[26] 吴岳,李敏,田育璋,等.CD44v6、E-cadhesion表达与乳腺浸润性癌预后的关系[J].肿瘤防治研究,2006,33(11):791-794.
[27] 陈萍,韩影,张玉华,等.乳腺癌中E-cadherin的表达及其临床病理意义[J]. 临床与实验病理学杂志,2004,20(6):715-717.
[28] 刘臻,张强,马文锋,等.乳腺癌中上皮钙黏蛋白和B-连环素的表达及其意义[J].中国普通外科杂志,2004,13(11):817-821.
[29] 刘树立,刘磐石,丁艳.乳腺癌中S100A4和上皮钙黏蛋白的表达及意义[J].中国医科大学学报,2004,33(4):358-359.
[30] 李晓鸣,晏红,朱任之.E-cadherin、β-catenin、CD44v6在乳腺癌中的表达[J].临床与实验病理学杂志,2003,19(5):510-513.
[31] 马忠良,张志谦,王占民,等.钙粘附素及连环素表达与乳腺癌转移及预后的关系[J].中国肿瘤临床,2003,30(5):316-324.
[32] 石胜军,段京彦,宋继谒.E-cadherin和Cathepsin D的表达与乳腺癌侵袭和转移的关系[J],诊断病理学杂志,2002,9(6):354-356.
[33] 谷化平,尚培中,刘艳茹.CD44v6和E-cadherin表达与乳腺癌生物学行为的关系[J].中国癌症杂志,2002,12(3):217-219.
[34] 赵书燕,张晓杰.E-Cadherin在乳腺癌中的表达及其意义[J].临床与实验病理学杂志,2000,16(3):217-218.
[35] Blick T,Widodo E,Hugo H,et al.Epithelialmesenchymal transition traits in human breast cancer cell lines[J]. Metastasis,2008,25:629-642.
[36] Jiang G,Zhang X,Zhang Y,et al.A novel biomarker C6orf106 promotes the malignant progression of breast cancer[J].Tumour Biol,2015,36:7881.
[37] Yu Z,Sun M,Jin F,et al.Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer[J].Oncol Rep,2015,34:165.
[38] Liu J,Sun X,Qin S,et al.CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer[J].Oncol Lett,2016,11:2635.

Meta-analysis of the relationship between E-cadherin and clinicopathological indicators in patients with breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[3]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[6]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[7]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[8]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[9]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[10]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[11]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[12]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.
[13]	XIAO Hongmei, PAN Tianqi, DONG Shunan, FU Lingmeng, WANG Shaokang, SUN Guiju. Menopausal status on risk for breast cancer from tea consumption: a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 395-399.
[14]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.
[15]	YANG Shaoyi, ZHANG Qingying, WU Jundong, LIN Qiuqiang, WANG Ruifeng, ZHENG Qingyuan, CAI Fen. Genetic variations in the mitotic checkpoint gene MAD1L1, and risk for breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 209-213.